Skip to main content

Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.

Clinical Trials

BRCC Research Institute 2026

< All Clinical Trials

Pumitamig vs. Durvalumab w/unresectable Stage II NSCLC w/o progression after platinum based concurrent chemoradiation

Disease Type: Lung

A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy.inum-based, concurrent chemoradiation therapy

Locations

Alleghany , Blacksburg , Roanoke , Salem , Wytheville

View on ClinicalTrials.gov